ifosfamide has been researched along with B-Cell Lymphoma in 45 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i." | 9.09 | High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001) |
| "We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m(2), day 1), ifosfamide (1500 mg/m(2) on days 3-7), etoposide (150 mg/m(2), days 3-5), cytarabine (100 mg/m(2), days 3-5) and dexamethasone (40 mg/body, days 3-5) (R-IVAD) for relapsed or refractory aggressive B-cell lymphoma." | 7.77 | An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. ( Hatta, Y; Hirabayashi, Y; Hojo, A; Iriyama, N; Kiso, S; Kobayashi, S; Kobayashi, Y; Kodaira, H; Kura, Y; Kurita, D; Miura, K; Sawada, U; Takei, K; Takeuchi, J; Tanaka, T; Yagi, M; Yamazaki, T, 2011) |
| "The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported." | 7.76 | Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with ( Azuma, T; Kim, SW; Kobayashi, Y; Maeshima, AM; Maruyama, D; Matsuno, Y; Mori, M; Munakata, W; Nomoto, J; Taniguchi, H; Tobinai, K; Watanabe, T, 2010) |
| "Standard treatment of transplant-eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL) consists of rituximab and platinum-based chemotherapy, either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone, cytarabine, and cisplatin (DHAP), with autologous transplant consolidation for those with chemosensitive disease." | 5.17 | Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. ( Czuczman, MS; Edvardsen, K; Fayad, L; Fecteau, D; Fennessy, M; Henkel, K; Jewell, RC; Joyce, R; Kharfan-Dabaja, MA; Liao, Q; Lisby, S; Lossos, IS; Matasar, MJ; Moskowitz, CH; Rodriguez, MA; Shea, TC; Singh, RP; Spitzer, G, 2013) |
| "One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i." | 5.09 | High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001) |
| "The safety and efficacy of rituximab with CODOX-M/IVAC (cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high dose cytarabine) was retrospectively analysed in 23 patients with non-human immunodeficiency virus-related B-cell non-Hodgkin lymphoma with proliferation index >95% [14 with classical Burkitt lymphoma (BL), five with B-cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma (DLBCL) and BL, and four with DLBCL]." | 3.77 | Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. ( Ardeshna, KM; Goldstone, AH; Kayani, I; Linch, DC; Lowry, L; Marafioti, T; Mohamedbhai, SG; Sibson, K, 2011) |
| "We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m(2), day 1), ifosfamide (1500 mg/m(2) on days 3-7), etoposide (150 mg/m(2), days 3-5), cytarabine (100 mg/m(2), days 3-5) and dexamethasone (40 mg/body, days 3-5) (R-IVAD) for relapsed or refractory aggressive B-cell lymphoma." | 3.77 | An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. ( Hatta, Y; Hirabayashi, Y; Hojo, A; Iriyama, N; Kiso, S; Kobayashi, S; Kobayashi, Y; Kodaira, H; Kura, Y; Kurita, D; Miura, K; Sawada, U; Takei, K; Takeuchi, J; Tanaka, T; Yagi, M; Yamazaki, T, 2011) |
| "The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported." | 3.76 | Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with ( Azuma, T; Kim, SW; Kobayashi, Y; Maeshima, AM; Maruyama, D; Matsuno, Y; Mori, M; Munakata, W; Nomoto, J; Taniguchi, H; Tobinai, K; Watanabe, T, 2010) |
| " Sequential dose intense ifosfamide, etoposide, carboplatin +/- rituximab was more toxic and no more effective than the same drugs given in a conventional fashion." | 2.74 | Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. ( Beaven, AW; Chao, N; Gabriel, DA; Garcia, RA; Gockerman, JP; Moore, DT; Rizzieri, DA; Serody, JS; Shea, TC, 2009) |
| "Febrile neutropenia was the most frequent grade 3 or 4 nonhematologic toxicity; it occurred in 7." | 2.71 | Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. ( Filippa, DA; Gencarelli, A; Kewalramani, T; Moskowitz, CH; Nimer, SD; Noy, A; O'Connor, O; Portlock, C; Qin, J; Straus, D; Teruya-Feldstein, J; Waxman, A; Yahalom, J; Zelenetz, AD, 2004) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | 2.68 | Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (8.89) | 18.2507 |
| 2000's | 29 (64.44) | 29.6817 |
| 2010's | 12 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Landsburg, DJ | 2 |
| Falkiewicz, MK | 1 |
| Maly, J | 1 |
| Blum, KA | 1 |
| Howlett, C | 1 |
| Feldman, T | 1 |
| Mato, AR | 1 |
| Hill, BT | 1 |
| Li, S | 1 |
| Medeiros, LJ | 2 |
| Torka, P | 1 |
| Hernandez-Ilizaliturri, F | 1 |
| Reddy, NM | 1 |
| Singavi, A | 1 |
| Fenske, TS | 2 |
| Chavez, JC | 2 |
| Kaplan, JB | 1 |
| Behdad, A | 1 |
| Petrich, AM | 2 |
| Bast, MA | 1 |
| Vose, JM | 1 |
| Olszewski, AJ | 1 |
| Costa, C | 1 |
| Lansigan, F | 1 |
| Gerson, JN | 1 |
| Barta, SK | 1 |
| Calzada, O | 1 |
| Cohen, JB | 1 |
| Lue, JK | 1 |
| Amengual, JE | 1 |
| Rivera, X | 1 |
| Persky, DO | 1 |
| Peace, DJ | 1 |
| Nathan, S | 1 |
| Cassaday, RD | 1 |
| Yang, XY | 1 |
| Jiang, L | 1 |
| Jia, RF | 1 |
| Hou, AJ | 1 |
| Turki, AT | 1 |
| Lamm, W | 1 |
| Liebregts, T | 1 |
| Dührsen, U | 1 |
| Matasar, MJ | 1 |
| Czuczman, MS | 1 |
| Rodriguez, MA | 1 |
| Fennessy, M | 1 |
| Shea, TC | 2 |
| Spitzer, G | 1 |
| Lossos, IS | 1 |
| Kharfan-Dabaja, MA | 1 |
| Joyce, R | 1 |
| Fayad, L | 1 |
| Henkel, K | 1 |
| Liao, Q | 1 |
| Edvardsen, K | 1 |
| Jewell, RC | 1 |
| Fecteau, D | 1 |
| Singh, RP | 1 |
| Lisby, S | 1 |
| Moskowitz, CH | 3 |
| Gisselbrecht, C | 2 |
| Abramson, JS | 1 |
| Sohani, AR | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Song, K | 1 |
| Zelenetz, AD | 3 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Jaso, J | 1 |
| Yang, DT | 1 |
| Nabhan, C | 1 |
| Menzel, H | 1 |
| Müller, A | 1 |
| Von Schilling, C | 1 |
| Licht, T | 1 |
| Peschel, C | 1 |
| Keller, U | 1 |
| Griffin, TC | 1 |
| Weitzman, S | 1 |
| Weinstein, H | 1 |
| Chang, M | 1 |
| Cairo, M | 1 |
| Hutchison, R | 1 |
| Shiramizu, B | 1 |
| Wiley, J | 1 |
| Woods, D | 1 |
| Barnich, M | 1 |
| Gross, TG | 1 |
| Beaven, AW | 1 |
| Moore, DT | 1 |
| Serody, JS | 1 |
| Gabriel, DA | 1 |
| Chao, N | 1 |
| Gockerman, JP | 1 |
| Garcia, RA | 1 |
| Rizzieri, DA | 1 |
| Tauro, S | 1 |
| Cochrane, L | 1 |
| Lauritzsen, GF | 1 |
| Baker, L | 1 |
| Delabie, J | 1 |
| Roberts, C | 1 |
| Mahendra, P | 1 |
| Holte, H | 1 |
| Mohamedbhai, SG | 1 |
| Sibson, K | 1 |
| Marafioti, T | 1 |
| Kayani, I | 1 |
| Lowry, L | 1 |
| Goldstone, AH | 1 |
| Linch, DC | 1 |
| Ardeshna, KM | 1 |
| Maruyama, D | 1 |
| Watanabe, T | 1 |
| Maeshima, AM | 1 |
| Nomoto, J | 1 |
| Taniguchi, H | 1 |
| Azuma, T | 1 |
| Mori, M | 1 |
| Munakata, W | 1 |
| Kim, SW | 1 |
| Kobayashi, Y | 2 |
| Matsuno, Y | 1 |
| Tobinai, K | 1 |
| Miura, K | 1 |
| Takei, K | 1 |
| Kobayashi, S | 1 |
| Kiso, S | 1 |
| Hirabayashi, Y | 1 |
| Hojo, A | 1 |
| Kodaira, H | 1 |
| Yagi, M | 1 |
| Kurita, D | 1 |
| Tanaka, T | 1 |
| Iriyama, N | 1 |
| Hatta, Y | 1 |
| Kura, Y | 1 |
| Yamazaki, T | 1 |
| Sawada, U | 1 |
| Takeuchi, J | 1 |
| Stewart, DA | 1 |
| Duan, Q | 1 |
| Carlson, L | 1 |
| Russell, JA | 1 |
| Bahlis, NJ | 1 |
| Duggan, P | 1 |
| Hasegawa, W | 1 |
| Voralia, M | 1 |
| Jarfaut, A | 1 |
| Santucci, R | 1 |
| Levêque, D | 1 |
| Herbrecht, R | 1 |
| Tang, JY | 1 |
| Pan, C | 1 |
| Chen, J | 1 |
| Chen, H | 1 |
| Wu, Y | 1 |
| Xue, H | 1 |
| Zhao, H | 1 |
| Gu, LJ | 1 |
| Fu, RY | 1 |
| Wang, YP | 1 |
| Mottl, H | 1 |
| Bajciova, V | 1 |
| Nemec, J | 1 |
| Al Shemmari, S | 1 |
| Al Awadi, S | 1 |
| Hamlin, PA | 1 |
| Kewalramani, T | 2 |
| Qin, J | 2 |
| Satagopan, JM | 1 |
| Verbel, D | 1 |
| Noy, A | 2 |
| Portlock, CS | 1 |
| Straus, DJ | 1 |
| Yahalom, J | 2 |
| Nimer, SD | 2 |
| Kawakami, K | 1 |
| Watanabe, Y | 1 |
| Kadowaki, S | 1 |
| Joyce, RM | 2 |
| Regan, M | 2 |
| Ottaway, J | 1 |
| Umiel, T | 2 |
| Tetreault, JC | 1 |
| Levine, J | 2 |
| McDermott, D | 2 |
| Hurley, D | 2 |
| Giallombardo, N | 2 |
| Smith, T | 1 |
| Lamontagne, D | 1 |
| Uhl, L | 2 |
| Avigan, D | 2 |
| Portlock, C | 1 |
| Straus, D | 1 |
| O'Connor, O | 1 |
| Filippa, DA | 1 |
| Teruya-Feldstein, J | 1 |
| Gencarelli, A | 1 |
| Waxman, A | 1 |
| Ueda, C | 1 |
| Nishikori, M | 1 |
| Kitawaki, T | 1 |
| Uchiyama, T | 1 |
| Ohno, H | 1 |
| Nath, SV | 1 |
| Seymour, JF | 1 |
| Jahnke, K | 1 |
| Wagner, T | 1 |
| Bechrakis, NE | 1 |
| Willerding, G | 1 |
| Coupland, SE | 1 |
| Fischer, L | 1 |
| Thiel, E | 1 |
| Korfel, A | 1 |
| Pereira, J | 1 |
| Bellesso, M | 1 |
| Pracchia, LF | 1 |
| Neto, AE | 1 |
| Beitler, B | 1 |
| de Almeida Macedo, MC | 1 |
| Dias, LC | 1 |
| Dorlhiac-Llacer, PE | 1 |
| Dulley, FL | 1 |
| Chamone, D | 1 |
| Fan, Y | 1 |
| Huang, ZY | 1 |
| Luo, LH | 1 |
| Yu, HF | 1 |
| Hara, S | 1 |
| Yokote, T | 1 |
| Oka, S | 1 |
| Akioka, T | 1 |
| Kobayashi, K | 1 |
| Tsuji, M | 1 |
| Hanafusa, T | 1 |
| Yokoyama, M | 1 |
| Kobayashi, T | 1 |
| Kubo, Y | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Corazzelli, G | 1 |
| Russo, F | 1 |
| Capobianco, G | 1 |
| Marcacci, G | 1 |
| Della Cioppa, P | 1 |
| Pinto, A | 1 |
| Hertzberg, MS | 1 |
| Crombie, C | 1 |
| Benson, W | 1 |
| Taper, J | 1 |
| Gottlieb, D | 1 |
| Bradstock, KF | 1 |
| Hagberg, H | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Bo, LJ | 1 |
| Liang, AB | 1 |
| Liu, B | 1 |
| Chen, YH | 1 |
| Wang, F | 1 |
| Jin, XP | 1 |
| Sugimoto, T | 1 |
| Matano, S | 1 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Simpson, L | 1 |
| Ansell, SM | 1 |
| Colgan, JP | 1 |
| Habermann, TM | 1 |
| Inwards, DJ | 1 |
| Ristow, KM | 1 |
| Johnston, PB | 1 |
| Markovic, SN | 1 |
| Micallef, IN | 1 |
| Porrata, LF | 1 |
| Witzig, TE | 1 |
| Vellenga, E | 1 |
| van Putten, WL | 1 |
| van 't Veer, MB | 1 |
| Zijlstra, JM | 1 |
| Fibbe, WE | 1 |
| van Oers, MH | 1 |
| Verdonck, LF | 1 |
| Wijermans, PW | 1 |
| van Imhoff, GW | 1 |
| Lugtenburg, PJ | 1 |
| Huijgens, PC | 1 |
| Csomor, J | 1 |
| Kaszás, I | 1 |
| Kollár, B | 1 |
| Pajor, L | 1 |
| Egyházi, Z | 1 |
| Fekete, S | 1 |
| Egyed, M | 1 |
| Timár, B | 1 |
| Reiter, A | 1 |
| Schrappe, M | 1 |
| Parwaresch, R | 1 |
| Henze, G | 1 |
| Müller-Weihrich, S | 1 |
| Sauter, S | 1 |
| Sykora, KW | 1 |
| Ludwig, WD | 1 |
| Gadner, H | 1 |
| Riehm, H | 1 |
| Tsujita, Y | 1 |
| Iwao, N | 1 |
| Makino, S | 1 |
| Ohsawa, N | 1 |
| Adde, M | 1 |
| Shad, A | 1 |
| Venzon, D | 1 |
| Arndt, C | 1 |
| Gootenberg, J | 1 |
| Neely, J | 1 |
| Nieder, M | 1 |
| Owen, W | 1 |
| Seibel, N | 1 |
| Wilson, W | 1 |
| Horak, ID | 1 |
| Magrath, I | 1 |
| Proctor, SJ | 1 |
| Taylor, PR | 1 |
| Angus, B | 1 |
| Wood, K | 1 |
| Lennard, AL | 1 |
| Lucraft, H | 1 |
| Carey, PJ | 1 |
| Stark, A | 1 |
| Iqbal, A | 1 |
| Haynes, A | 1 |
| Russel, N | 1 |
| Leonard, RC | 1 |
| Culligan, D | 1 |
| Conn, J | 1 |
| Jackson, GH | 1 |
| Kraser, CN | 1 |
| Tetrealt, JC | 1 |
| Davis, TA | 1 |
| Hsu, FJ | 1 |
| Caspar, CB | 1 |
| van Beckhoven, A | 1 |
| Czerwinsk, DK | 1 |
| Liles, TM | 1 |
| Taidi, B | 1 |
| Benike, CJ | 1 |
| Engleman, EG | 1 |
| Levy, R | 1 |
| Moskowitz, C | 1 |
| Wada, S | 1 |
| Kitamura, H | 1 |
| Matsuura, Y | 1 |
| Katayama, Y | 1 |
| Ohkawa, H | 1 |
| Kugai, N | 1 |
| Motoyoshi, K | 1 |
| Fuse, Y | 1 |
| Nagata, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Arm, Safety and Efficacy Study of Ofatumumab in Combination With ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma Prior to Autologous Stem Cell Transplantation[NCT00823719] | Phase 2 | 61 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma[NCT00144092] | Phase 2 | 60 participants (Anticipated) | Interventional | 2001-05-31 | Completed | ||
| Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995] | Phase 3 | 481 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| Cytoreduction and Stem Cell Mobilization With Rituximab and ICE for Patients With Refractory or Relapsed CD20+ B-Cell IGL Eligible for ASCT: The RICE Protocol[NCT00005631] | Phase 2 | 0 participants | Interventional | 1999-11-30 | Completed | ||
| A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY)[NCT00012051] | Phase 3 | 340 participants (Anticipated) | Interventional | 2000-09-30 | Completed | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CL is the clearance of drug from plasma, which is defined as the volume of plasma from which drug is removed per unit time. (NCT00823719)
Timeframe: Study Day 1 up to Study Day 85 (up to 12 weeks)
| Intervention | mL/hr (Geometric Mean) |
|---|---|
| Ofatumumab + DHAP | 8.7 |
| Ofatumumab + ICE | 9.2 |
| Total Ofatumumab + Chemotherapy | 9.0 |
CR is defined as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | participants (Number) |
|---|---|
| Ofatumumab + DHAP | 11 |
| Ofatumumab + ICE | 11 |
| Total Ofatumumab + Chemotherapy | 22 |
Responders with OR included participants with complete response (CR) and partial response (PR). This was based on adequate responses from the investigator assessment after the completion of treatment. CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR: at least a 50% decrease from baseline in the sum of the product of the diameters of target lesions. (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | participants (Number) |
|---|---|
| Ofatumumab + DHAP | 18 |
| Ofatumumab + ICE | 18 |
| Total Ofatumumab + Chemotherapy | 36 |
CD34+ cells are a mixture of stem cells and white blood cells of various degrees of maturity. Stem cell mobilization is the process of stimulating the hematopoietic stem cells (CD34+) to move out of the bone marrow and into the bloodstream, where they can be collected via a process called apheresis. Successful mobilization was defined as the collection of >2x10^6 CD34+ cells/kg. Only those participants, who commenced mobilization, following the administration of ofatumumab in combination with either ICE or DHAP combination chemotherapy, were assessed. (NCT00823719)
Timeframe: During treatment Cycle 2 (Study Days 22-42) and/or Cycle 3 (Study Days 43-63)
| Intervention | participants (Number) |
|---|---|
| Ofatumumab + DHAP | 23 |
| Ofatumumab + ICE | 20 |
| Total Ofatumumab + Chemotherapy | 43 |
Overall survival is defined as the interval of time between the date of treatment start and the date of death due to any cause. For participants who did not die, time of death was censored at the date of last contact. (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | days (Median) |
|---|---|
| Ofatumumab + DHAP | 433.0 |
| Ofatumumab + ICE | NA |
| Total Ofatumumab + Chemotherapy | 508.0 |
PFS is defined as the interval of time between the date of treatment start and the earlier of the date of disease progression and the date of death due to any cause. Disease progression was based on the assessments locally by investigators for the disease under study. Disease progression was based on imaging data or clinical assessment data (if radiologic assessment data were not possible or assessment was not performed). (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | days (Median) |
|---|---|
| Ofatumumab + DHAP | 301.0 |
| Ofatumumab + ICE | 288.0 |
| Total Ofatumumab + Chemotherapy | 288.0 |
t1/2 is defined as terminal phase half-life, which is the time required for the amount of the drug in the body to decrease by half. (NCT00823719)
Timeframe: Study Day 1 up to Study Day 85 (up to 12 weeks)
| Intervention | hr (Geometric Mean) |
|---|---|
| Ofatumumab + DHAP | 595 |
| Ofatumumab + ICE | 646 |
| Total Ofatumumab + Chemotherapy | 624 |
Vss is the apparent volume of distribution when plasma concentrations are measured under steady state conditions. At steady state, the plasma concentration-time profile of the drug is similar after each dose. (NCT00823719)
Timeframe: Study Day 1 up to Study Day 85 (up to 12 weeks)
| Intervention | Liters (Geometric Mean) |
|---|---|
| Ofatumumab + DHAP | 7.12 |
| Ofatumumab + ICE | 8.13 |
| Total Ofatumumab + Chemotherapy | 7.68 |
AUC(0-tau) is the area under the plasma concentration-time curve from time zero (0) over the dosing interval, tau, and is a measure of drug exposure. Tau is 21 days (504 hours) in this study. (NCT00823719)
Timeframe: Cycle 3 (Study Day 43; 3 weeks)
| Intervention | µg*hr/mL (Geometric Mean) | ||
|---|---|---|---|
| Cycle 3, 300 mg; n=4, 6, 10 | Cycle 3, 1000 mg; n=14, 13, 30 | Cycle 3 both doses; n=18, 19, 40 | |
| Ofatumumab + DHAP | 95112 | 112676 | 108511 |
| Ofatumumab + ICE | 83385 | 95341 | 91391 |
| Total Ofatumumab + Chemotherapy | 87891 | 101948 | 98236 |
AUC is defined as the area under the ofatumumab (Ofa) concentration-time curve as a measure of drug exposure. AUC(0-inf) is AUC from the start of infusion extrapolated to infinite time. Results are reported by first dose group and combined, as appropriate. (NCT00823719)
Timeframe: Cycle 1 Day 1 (Study Day 1; up to 1 week) and Cycle 3 (Study Day 43; up to 6 weeks)
| Intervention | µg*hr/mL (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Cycle 1 Day 1, 300 mg; n=4, 17, 21 | Cycle 1 Day 1, 1000 mg; n=22, 18, 40 | Cycle 3, 300 mg; n=4, 6, 10 | Cycle 3, 1000 mg; n=14, 13, 30 | Cycle 3, both doses; n=18, 19, 40 | |
| Ofatumumab + DHAP | 34056 | 115741 | 222713 | 258487 | 250070 |
| Ofatumumab + ICE | 33606 | 105898 | 206389 | 216885 | 213514 |
| Total Ofatumumab + Chemotherapy | 33691 | 111203 | 212770 | 232310 | 227263 |
Cmax is defined as the maximum concentration of drug in plasma samples for the dosing occasion. (NCT00823719)
Timeframe: Cycle 1 Day 1 (Study Day 1; up to 48 hours), Cycle 1 Day 8 (Study Day 8; up to 24 hours), Cycle 3 (Study Day 43; up to 48 hours)
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1, 300 mg; n=4, 17, 21 | Cycle 1 Day 1, 1000 mg; n=22, 18, 40 | Cycle 1 Day 8, 300 mg; n=4, 13, 17 | Cycle 1 Day 8, 1000 mg; n=21, 18, 39 | Cycle 3, 300 mg; n=4, 11, 15 | Cycle 3, 1000 mg; n=14, 14, 33 | Cycle 3, both doses; n=18, 25, 48 | |
| Ofatumumab + DHAP | 89.8 | 323 | 245 | 431 | 416 | 466 | 455 |
| Ofatumumab + ICE | 80.0 | 268 | 273 | 368 | 417 | 397 | 406 |
| Total Ofatumumab + Chemotherapy | 81.8 | 297 | 266 | 401 | 417 | 421 | 420 |
Human anti-human antibodies (HAHA) indicate immune response to the administered human monoclonal antibody in a two-step assay. A positive screening result is confirmed in a second step. Negative Conclusive is subset of Negative and is a negative HAHA test result with an ofatumumab concentration <200 µg/mL in a pharmacokinetic sample collected at the same time as the HAHA sample. Data are presented when a HAHA sample was collected. WD, withdrawal; FU, follow up. (NCT00823719)
Timeframe: Study Day 1 up to approximately Study Day 63
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Positive at Day 1; n=26, 35, 61 | Negative at Day 1; n=26, 35, 61 | Positive at Early WD or FU; n=24, 30, 54 | Negative at Early WD or FU; n=24, 30, 54 | Negative conclusive at Early WD or FU; n=24, 30, 5 | |
| Ofatumumab + DHAP | 0 | 26 | 0 | 24 | 18 |
| Ofatumumab + ICE | 0 | 35 | 0 | 30 | 28 |
| Total Ofatumumab + Chemotherapy | 0 | 61 | 0 | 54 | 46 |
Neutropenia is defined as an abnormal decrease in the number of neutrophils (type of white blood cell in blood) in the blood. Febrile neutropenia is the development of fever in participants with neutropenia. Pancytopenia is defined as inadequate blood-cell formation by bone marrow, resulting in a lack of all blood-cell types. (NCT00823719)
Timeframe: Study Day 1 to approximately Study Day 63
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any Event of Decreased Neutrophils; n=26, 35, 61 | Neutropenia; n=12, 11, 23 | Febrile Neutropenia; n=12, 11, 23 | Pancytopenia; n=12, 11, 23 | |
| Ofatumumab + DHAP | 12 | 7 | 8 | 1 |
| Ofatumumab + ICE | 11 | 11 | 1 | 0 |
| Total Ofatumumab + Chemotherapy | 23 | 18 | 9 | 1 |
Anaemia is defined as a pathological deficiency in the oxygen-carrying component of the blood, measured in unit volume concentrations of hemoglobin, red blood-cell volume, or red blood-cell number. Pancytopenia is defined as inadequate blood-cell formation by bone marrow, resulting in a lack of all blood-cell types. (NCT00823719)
Timeframe: Study Day 1 to approximately Study Day 63
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any Event of Decreased Hemoglobin; n=26, 35, 61 | Anaemia; n=16, 18, 34 | Haemoglobin Decreased; n=16, 18, 34 | Pancytopenia; n=16, 18, 34 | |
| Ofatumumab + DHAP | 16 | 14 | 3 | 1 |
| Ofatumumab + ICE | 18 | 16 | 2 | 0 |
| Total Ofatumumab + Chemotherapy | 34 | 30 | 5 | 1 |
Thrombocytopenia is defined as an abnormal decrease in the number of platelets in circulatory blood. Pancytopenia is defined as inadequate blood-cell formation by bone marrow, resulting in a lack of all blood-cell types. (NCT00823719)
Timeframe: Study Day 1 to approximately Study Day 63
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any Event of Decreased Platelets; n=26, 35, 61 | Thrombocytopenia; n=21, 19, 40 | Pancytopenia; n=21, 19, 40 | |
| Ofatumumab + DHAP | 21 | 20 | 1 |
| Ofatumumab + ICE | 19 | 19 | 0 |
| Total Ofatumumab + Chemotherapy | 40 | 39 | 1 |
Ctrough is defined as the trough plasma concentration, which is the measured concentration at the end of a dosing interval (taken directly before the start of the next infusion). (NCT00823719)
Timeframe: Cycle 1 Day 8 (Study Day 8; up to 8 hours prior to infusion start), Cycle 2 (Study Day 22; up to 7 hours prior to infusion start), Cycle 3 (Study Day 43; up to 6 hours prior to infusion start)
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8, 300 mg; n=4, 15, 19 | Cycle 1 Day 8, 1000 mg; n=19, 18, 37 | Cycle 2, 300 mg; n=4, 16, 20 | Cycle 2, 1000 mg; n=21, 18, 39 | Cycle 3, 300 mg; n=4, 13, 17 | Cycle 3, 1000 mg; n=18, 18, 40 | Cycle 3, both doses; n=22, 31, 57 | |
| Ofatumumab + DHAP | 31.8 | 95.8 | 112 | 138 | 120 | 153 | 146 |
| Ofatumumab + ICE | 28.3 | 106 | 71.5 | 147 | 76.7 | 122 | 100 |
| Total Ofatumumab + Chemotherapy | 29.1 | 101 | 78.2 | 142 | 85.2 | 134 | 117 |
18 trials available for ifosfamide and B-Cell Lymphoma
| Article | Year |
|---|---|
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Feasibility Stu | 2009 |
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cohort Studies; | 2010 |
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Outcome of B-cell non-Hodgkin lymphoma protocol CCCG-B NHL97: a report from Chinese multi-center cooperative group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Cyclopho | 2002 |
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic | 2003 |
A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2003 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cytarabine; Developing Co | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2006 |
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1995 |
Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 1998 |
Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 1998 |
Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 1998 |
Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 1998 |
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Ho | 2001 |
Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineo | 2001 |
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Antibodies, Anti-Idiotypic; Antibodies, N | 2001 |
27 other studies available for ifosfamide and B-Cell Lymphoma
| Article | Year |
|---|---|
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Treatment of grey zone lymphoma using the R-CODOX-M/R-IVAC protocol: Two case reports.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubici | 2017 |
R-ICE Chemotherapy with or without Autologous Transplantation for Elderly Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; Etopos | 2018 |
Ofatumumab in diffuse large B cell lymphoma?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2013 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Ant | 2013 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 2003 |
[Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; | 2003 |
Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chromosomes, Human; Chromosomes, Human, | 2004 |
Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2005 |
Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Cyclophosphamide; Disease-Free Survival; Eye Neoplasms; Hum | 2005 |
[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neo | 2005 |
Bronchial infiltration with diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2006 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplati | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytarabine; Dex | 2007 |
Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2008 |
[Syndrome of inappropriate secretion of antidiuretic hormone and neurotoxicity induced by vincristine and alkylating agents during chemotherapy for malignant lymphoma of thyroid gland].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; C | 1998 |
Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administrat | 2002 |
Parathyroid hormone-related protein as a cause of hypercalcemia in a B-cell type malignant lymphoma.
Topics: Aclarubicin; Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Calcitriol | 1992 |